Abstract 253P
Background
Pretreatment diagnosis by diffusion-weighted magnetic resonance imaging (DW-MRI) is useful to determine the effect of chemotherapy for gastric cancer. Here, we investigated the relationship among DW-MRI, endoscopy, and tumor markers.
Methods
Eight patients underwent hemostatic radiotherapy (RT) for gastric cancer in this prospective study from 2019 to 2021. The patients completed MRI, endoscopy, and blood tests before RT; MRI, endoscopy, and blood tests 1 month after RT; and MRI and blood tests 3 months after RT. Correlations between changes in apparent diffusion coefficient (ADC) derived from DW-MRI and the tumor marker carcinoembryonic antigen (CEA) were investigated.
Results
Univariate analysis of overall survival showed that sex and chemotherapy treatment were statistically significant factors. The CEA values before and 1 month after RT decreased significantly. There was no statistical difference between the CEA value 1 and 3 months after RT. The ADC value before and 1 month after RT increased significantly but not between 1 and 3 months after RT. Comparing the ratio of ADC before RT to 1 (or 3) month(s) after RT with that of CEA before RT to 1 (or 3) month(s) after RT, we found an inverse relationship between the two ratios.
Conclusions
The usefulness of DW-MRI has been reported mainly for solid tumors. Herein, we evaluated the usefulness of DW-MRI for gastric cancer using a tumor marker in RT settings. We showed that changes in the ADC values and changes in the CEA values are correlated using ratios (before/1 or 3 months after RT). Additionally, 3 months after treatment, a decrease in ADC appeared earlier than a decrease in CEA. Our findings suggest that ADC may represent biological changes earlier than CEA.
Clinical trial identification
CTR-UMIN000026362.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03